BUSINESS WIRE
BEVERLY, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation announced today that it has begun
enrollment in a Phase 1 clinical trial with the Company’s
selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma.
In March, Inotek received approval from the U.S. Food and Drug
Administration to advance INO-8875 into clinical trials. The initial
study will evaluate the safety, tolerability, and the potential of
INO-8875 to lower intraocular pressure (IOP) in glaucoma patients.
Glaucoma patients typically have elevated levels of IOP which can damage
the optic nerve of the eye and lead to partial or complete loss of
vision.
“We are pleased that our clinical program in
glaucoma is progressing and I am encouraged by the strength of our
preclinical data supporting the potential role of Adenosine 1 receptor
agonists in managing intraocular pressure,”
said Dr. Rudolf Baumgartner, Inotek’s Chief
Medical Officer. “New mechanisms for lowering
IOP are needed to provide physicians with alternatives for the treatment
of this chronic and progressive ocular disease –
especially given the expanding population of glaucoma patients. Highly
selective Adenosine 1 receptor agonists, such as ours, may provide a
meaningful new approach for the management of glaucoma.”
Inotek has several other promising drugs in preclinical development
targeting various ophthalmology indications including such underserved
diseases as diabetic retinopathy, age-related macular degeneration and
uveitis.
Additionally, Inotek has several non-ophthalmology programs in
development including, 1) a second clinical stage compound, INO-4885,
currently in Phase 1 clinical safety trials which is being developed as
a treatment for contrast induced nephropathy, 2) a monoclonal antibody
program in preclinical development, targeting the flagellin/TLR5 pathway
which is associated with inflammatory bowel disease and 3) a preclinical
PARP inhibitor program in development for oncology.
About Inotek Pharmaceuticals
Inotek is a clinical-stage, drug development company located in
Massachusetts with two clinical stage programs, targeting applications
in glaucoma and contrast induced nephropathy. The Company’s
preclinical programs include products in development for various other
ophthalmology indications spanning multiple different therapeutic
mechanisms believed to play a role in ocular disease progression. Inotek
also has preclinical programs targeting PARP and flagellin with
applications in cancer and inflammatory bowel disease.